Novavax, Inc. to Present RSV Vaccine Clinical and Preclinical Results at ICAAC

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage biopharmaceutical company creating novel vaccines based on recombinant nanoparticle technology, today announced that it will present data from recent clinical and preclinical studies of its respiratory syncytial virus F-protein (RSV F) nanoparticle vaccine candidate in poster sessions at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver Colorado, September 11-13, 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news